The clinical research industry is no longer debating whether to use AI, it’s figuring out how to scale it. Medidata’s second annual survey, conducted by Everest Group, reveals a widening gap between organizations that adopted AI early and everyone else. The impact is clear: those with 18+ months of experience report improvements in trial timelines (72.9%) and protocol deviation reduction (67.5%) while the broader industry trails behind. With 92% of respondents increasing AI investment and 82% expecting 2-3x returns, optimism around AI’s potential is strong across the board. The organizations that overcome scaling barriers now will be the ones who see meaningful results and set the pace moving forward.
What’s Inside the 2026 Report
The Early Adopter Advantage: See where experienced organizations are reporting above expectation results.
Where AI Delivers Today: Discover where AI is moving the needle, with 86.5% seeing improvements in high-volume, rules-based workflows.
Navigating Barriers to Scale: Learn the hurdles holding organizations back from enterprise-wide implementation, and what early adopters did to overcome them.
From Automation to Prediction: Gain insights on the move toward protocol simulation, virtual twins, and autonomous agents.
Download the report to see where the industry’s seeing AI impact and what it takes to close the scaling gap.
Medidata has been powering smarter treatments and healthier people by supporting clinical trials through groundbreaking technological innovations for over 25 years. Medidata is a leader in AI-powered solutions across the entire trial lifecycle to accelerate clinical breakthroughs, reduce patient and site burden, and bring new therapies to market faster. Supported by one of the largest clinical datasets in the industry of more than 38,000 trials and 12 million patients, Medidata's Study, Patient, and Data Experiences are trusted by more than 1 million registered users across approximately 2,300 customers. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and is recognized as a leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast, from Dreamers to Disruptors, and follow us at @medidata-solutions on LinkedIn.
Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.
Anthropic’s Gates Foundation Partnership and Healthcare AI
See how Anthropic's Gates Foundation partnership and Long-Term Benefit Trust could lead the way in shaping responsible AI governance across healthcare innovation.
AI in Healthcare: OpenAI and Epic Integration Connects EHRs
OpenAI and Epic integration brings AI healthcare into EHR workflows, connecting patient records with ChatGPT for Healthcare to advance research and patient care.
<p>Founded in 2004, Ametris (formerly ActiGraph) is a global digital health solutions provider transforming real-world patient data into validated clinical evidence. Our end-to-end platform combines advanced wearables, regulatory-aligned analytics, and expert scientific support across every phase of a clinical trial. We serve leading pharmaceutical, biotech, and public health research organizations worldwide, backed by two decades of experience and a collaborative, science-first approach.</p><p>In 2026, Ametris joined Signant Health, uniting wearable-derived digital outcome measures with industry-leading eCOA solutions to give sponsors a single partner for integrated evidence generation, combining continuous sensor data with patient-reported outcomes.</p>
Image
Clinical Development
<p><a href="https://www.medidata.com/en/">Medidata </a>has been powering smarter treatments and healthier people by supporting clinical trials through groundbreaking technological innovations for over 25 years. Medidata is a leader in AI-powered solutions across the entire trial lifecycle to accelerate clinical breakthroughs, reduce patient and site burden, and bring new therapies to market faster. Supported by one of the largest clinical datasets in the industry of more than 38,000 trials and 12 million patients, Medidata's <a href="https://www.medidata.com/en/experiences/study-experience/">Study</a>, <a href="https://www.medidata.com/en/experiences/patient-experience/">Patient</a>, and <a href="https://www.medidata.com/en/experiences/data-experience/">Data</a> Experiences are trusted by more than 1 million registered users across approximately 2,300 customers. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and is recognized as a leader by Everest Group and IDC. Discover more at <a href="https://www.medidata.com/">www.medidata.com</a><strong>. </strong>Listen to our latest podcast, <a href="https://www.medidata.com/en/from-dreamers-to-disruptors-podcast/"><em>from Dreamers to Disruptors</em></a>,<strong> </strong>and follow us at @medidata-solutions on LinkedIn.</p>
